Aktis Oncology, Inc. (AKTS)
18.15
+0.41
(+2.31%)
USD |
NASDAQ |
Oct 09, 16:00
18.14
-0.02
(-0.08%)
After-Hours: 20:00
Aktis Oncology Net Income (Quarterly) : -24.14M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -24.14M |
| March 31, 2026 | -18.32M |
| December 31, 2025 | -15.14M |
| Date | Value |
|---|---|
| June 30, 2025 | -18.08M |
| March 31, 2025 | -14.98M |
| December 31, 2024 | -12.06M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.384M |
| Total Expenses (Quarterly) | 27.53M |
| EPS Diluted (Quarterly) | -0.4364 |
| Enterprise Value | 497.96M |
| Gross Profit Margin (Quarterly) | 74.02% |
| Profit Margin (Quarterly) | -713.5% |
| Earnings Yield | -7.59% |
| Normalized Earnings Yield | -7.593 |